18/01/2026
🔬 AesMed at FUE ASIA SAARC Regional Workshop 2026 🌏
At the FUE ASIA SAARC Regional Workshop 2026, AesMed introduced its advanced treatment framework,
CytoMesopecia – Cytokines Mesotherapy for Alopecia, to the global hair-loss medical community.
At the core of CytoMesopecia is AGF39, AesMed’s proprietary cytokine-based solution.
AGF39 has been actively used in leading hair-loss treatment hospitals and clinics across Korea, Japan, China, and other Asian markets, accumulating one of the largest numbers of clinical procedures among cytokine mesotherapy solutions.
📊 Why AGF39 Matters
• Supported by extensive real-world clinical experience
• Designed for professional mesotherapy delivery to the scalp dermis
• Aims to optimize the follicular microenvironment and support anagen phase maintenance
• Easily integrated into daily clinical workflows and combination treatment protocols
At the conference, many medical professionals showed strong interest in AGF39’s clinical credibility, high procedure volume, and its role in advancing regenerative, biologically driven alopecia care beyond conventional approaches.
Through continued global engagement and collaboration, AesMed remains committed to supporting medical professionals with science-based solutions that reflect real clinical needs.
🔗 Learn more about AesMed: www.aesmed.co.kr